
GSK to Buy Sierra Oncology for £1.5 Billion
British drugs giant GlaxoSmithKline (GSK) is buying US cancer treatment developer Sierra Oncology for £1.5 billion in a deal observers see as designed to fend off pressure from activist shareholder Elliott Management, which has been pushing the company to expand its pipeline.








































